US 2025/0019436 A1 · Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof

Abstract

The present invention belongs to the field of biomedicine, and relates to a bispecific antibody against TIGIT and PD-L1, and a pharmaceutical composition thereof and the use thereof. The bispecific antibody of the present invention comprises: a TIGIT-targeting first protein functional region and a PD-L1-targeting second protein functional region, wherein the first protein functional region is an anti-TIGIT antibody or an antigen-binding fragment thereof, the heavy chain variable region of the anti-TIGIT antibody contains HCDR1 having an amino acid sequence as shown in SEQ ID NO: 10, HCDR2 having an amino acid sequence as shown in SEQ ID NO: 11 and HCDR3 having an amino acid sequence as shown in SEQ ID NO: 12, and the light chain variable region of the anti-TIGIT antibody contains LCDR1 having an amino acid sequence as shown in SEQ ID NO: 13, LCDR2 having an amino acid sequence as shown in SEQ ID NO: 14 and LCDR3 having an amino acid sequence as shown in SEQ ID NO: 15. The bispecific antibody of the present invention has high affinity to dual targets, i.e. TIGIT and PD-L1, and has good application prospects.

Claims22

Dependent claims

A bispecific antibody, which comprises:

a first protein functional region targeting TIGIT, and
a second protein functional region targeting a target different from TIGIT;
wherein:
the first protein functional region is an anti-TIGIT immunoglobulin or an antigen-binding fragment thereof;
the heavy chain variable region of the anti-TIGIT immunoglobulin comprises HCDR1 with the amino acid sequence as set forth in SEQ ID NO:
10, HCDR2 with the amino acid sequence as set forth in SEQ ID NO:
11, and HCDR3 with the amino acid sequence as set forth in SEQ ID NO:
12;
and
the light chain variable region of the anti-TIGIT immunoglobulin comprises LCDR1 with the amino acid sequence as set forth in SEQ ID NO:
13, LCDR2 with the amino acid sequence as set forth in SEQ ID NO:
14, and LCDR3 with the amino acid sequence as set forth in SEQ ID NO:
15.

10 more elements

Dependencies are inferred from the claim text.

Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof

Life of this patent

Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof

Life of this patent

Abstract

Claims22